These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 20394970

  • 1. Contemporary cost analysis of single instillation of mitomycin after transurethral resection of bladder tumor in a universal health care system.
    Feifer A, Xie X, Brophy JM, Segal R, Kassouf W.
    Urology; 2010 Sep; 76(3):652-6. PubMed ID: 20394970
    [Abstract] [Full Text] [Related]

  • 2. Increasing medical staff safety by using a closed system for intravesical instillation of mitomycin C.
    Haifler M, Lang E, Sabler I, Gutman Y, Lindner A, Zisman A.
    Urology; 2010 Sep; 76(3):649-51. PubMed ID: 20493518
    [Abstract] [Full Text] [Related]

  • 3. Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases.
    Lee CT, Barocas D, Globe DR, Oefelein MG, Colayco DC, Bruno A, O'Day K, Bramley T.
    J Urol; 2012 Dec; 188(6):2114-9. PubMed ID: 23083857
    [Abstract] [Full Text] [Related]

  • 4. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT, Yildirim U, Zorlu F, Ozen H.
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [Abstract] [Full Text] [Related]

  • 5. Single instillation of mitomycin C reduces 1st year recurrence following transurethral resection of non-muscle invasive bladder cancer.
    Ather MH, Aziz S, Sulaiman MN.
    J Ayub Med Coll Abbottabad; 2007 May; 19(4):18-20. PubMed ID: 18693589
    [Abstract] [Full Text] [Related]

  • 6. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
    O'Brien T, Ray E, Chatterton K, Khan MS, Chandra A, Thomas K.
    BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
    [Abstract] [Full Text] [Related]

  • 7. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
    Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, Solsona E, Di Stasi SM, Witjes JA.
    Eur Urol; 2009 Aug; 56(2):247-56. PubMed ID: 19409692
    [Abstract] [Full Text] [Related]

  • 8. Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor.
    Maeda T, Kikuchi E, Matsumoto K, Miyajima A, Oya M.
    J Urol; 2011 Mar; 185(3):802-6. PubMed ID: 21239010
    [Abstract] [Full Text] [Related]

  • 9. Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer.
    Mostafid AH, Rajkumar RG, Stewart AB, Singh R.
    BJU Int; 2006 Mar; 97(3):509-12. PubMed ID: 16469017
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup.
    Solsona E, Iborra I, Ricós JV, Monrós JL, Casanova J, Dumont R.
    J Urol; 1999 Apr; 161(4):1120-3. PubMed ID: 10081851
    [Abstract] [Full Text] [Related]

  • 11. Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy.
    Seo HK, Cho KS, Chung J, Joung JY, Park WS, Chung MK, Lee KH.
    Urology; 2010 Aug; 76(2):512.e1-7. PubMed ID: 20579709
    [Abstract] [Full Text] [Related]

  • 12. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
    Järvinen R, Kaasinen E, Sankila A, Rintala E, FinnBladder Group.
    Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey.
    Nielsen ME, Smith AB, Pruthi RS, Guzzo TJ, Amiel G, Shore N, Lotan Y.
    BJU Int; 2012 Oct; 110(7):967-72. PubMed ID: 22487336
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection.
    Shapiro O, Jones K, Wang C, Landas S, Haas GP.
    Can J Urol; 2006 Dec; 13(6):3317-20. PubMed ID: 17187694
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cost-effective treatment of low-risk carcinoma not invading bladder muscle.
    Green DA, Rink M, Cha EK, Xylinas E, Chughtai B, Scherr DS, Shariat SF, Lee RK.
    BJU Int; 2013 Mar; 111(3 Pt B):E78-84. PubMed ID: 22958598
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
    Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Navarra P, Massoud R, Vespasiani G.
    J Urol; 2003 Sep; 170(3):777-82. PubMed ID: 12913696
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.